The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Open accessAbstract
The aim of this review was to summarize current available information about the role of phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling in cancer as a potential target for new therapy options. The mTOR and PI3K/AKT/mTORC1 (mTOR complex 1) signaling are critical for the regulation of many fundamental cell processes including protein synthesis, cell growth, metabolism, survival, catabolism, and autophagy, and deregulated mTOR signaling is implicated in cancer, metabolic dysregulation, and the aging process. In this review, we summarize the information about the structure and function of the mTOR pathway and discuss the mechanisms of its deregulation in human cancers including genetic alterations of PI3K/AKT/mTOR pathway components. We also present recent data regarding the PI3K/AKT/mTOR inhibitors in clinical studies and the treatment of cancer, as well the attendant problems of resistance and adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 3×
“Amino acids stimulate the loading of RagA or RagB with GTP, which enables RagA/B to interact with the RAPTOR component of mTORC1 [77].”
BackgroundmTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy
Hardie, D. G. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2249 · Cited by 2,216
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
Regulation of TORC1 by Rag GTPases in nutrient response
Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P., & Guan, K.-L. (2008) · Nature Cell Biology · doi:10.1038/ncb1753 · Cited by 1,349 · cited 2×
“The amino acid-dependent activation of mTORC1 requires the Rag subfamily of Ras small GTPases [76,77].”
BackgroundRegulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Signalling through the lipid products of phosphoinositide-3-OH kinase
Toker, A., & Cantley, L. C. (1997) · Nature · doi:10.1038/42648 · Cited by 1,304
The nuts and bolts of AGC protein kinases
Pearce, L. R., Komander, D., & Alessi, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2822 · Cited by 1,294
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · cited 4×
“TSC can also be inhibited by the TSC2 phosphorylation by the MAP (mitogen-activated protein) kinase extracellular signal-regulated kinase (ERK) [51] and p90 ribosomal S6 kinase (RSK) [52], two downstream substrates of the Ras receptor tyrosine kinase signaling pathway.”
BackgroundInfluentialHolz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 7×
“Sci. 2021, 22, 1743 20 of 27 PIKK phosphatidylinositol 3-kinase-related kinase PI(4,5)P2 phosphatidylinositol 4,5 bisphosphate PI(3,4,5)P3 phosphatidylinositol 3,4,5 trisphosphate PLD phospholipase D PRAS40 proline-rich AKT1 substrate 1 Protor protein observed with RICTOR PTEN phosphatase and tensin homolog RAPTOR reg…”
BackgroundInfluentialPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Chung, J., Kuo, C. J., Crabtree, G. R., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90643-q · Cited by 1,150
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,080
mTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., McCormick, F., Tempst, P., et al. (1998) · Science · doi:10.1126/science.279.5351.710 · Cited by 1,059
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · cited 1×
“It has been shown that many cancer cells are characterized by EGFR hyperactivation, gene amplification leading to receptor overexpression, or mutants with dysregulated signaling [123].”
BackgroundTargeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Crystal Structure of the PTEN Tumor Suppressor
Lee, J.-O., Yang, H., Georgescu, M.-M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P., & Pavletich, N. P. (1999) · Cell · doi:10.1016/s0092-8674(00)81663-3 · Cited by 1,014
Rheb Binds and Regulates the mTOR Kinase
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Kim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
Regulation of mTORC1 by PI3K signaling
Dibble, C. C., & Cantley, L. C. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.06.002 · Cited by 836
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1056 · Cited by 810
PDK1, the master regulator of AGC kinase signal transduction
Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.022 · Cited by 810
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
Menon, S., Dibble, C. C., Talbott, G., Hoxhaj, G., Valvezan, A. J., Takahashi, H., Cantley, L. C., & Manning, B. D. (2014) · Cell · doi:10.1016/j.cell.2013.11.049 · Cited by 766
Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J. M., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 757
Mammalian target of rapamycin: a central node of complex signaling cascades.
Dobashi, Y., Watanabe, Y., Miwa, C., Suzuki, S., & Koyama, S. (2011) · PubMed · Cited by 750
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth
Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E., & Pagano, M. (2006) · Science · doi:10.1126/science.1130276 · Cited by 731
Structure, regulation and function of PKB/AKT—a major therapeutic target
Hanada, M., Feng, J., & Hemmings, B. A. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.009 · Cited by 719
Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 696
Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K.-I., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 682
mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1
Dibble, C. C., Elis, W., Menon, S., Qin, W., Klekota, J., Asara, J. M., Finan, P. M., Kwiatkowski, D. J., Murphy, L. O., & Manning, B. D. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.009 · Cited by 612
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
PTEN: a tumour suppressor that functions as a phospholipid phosphatase
Maehama, T. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01519-6 · Cited by 590
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products
van Slegtenhorst, M. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.6.1053 · Cited by 565
Zhang, J.-G., Wang, J.-J., Zhao, F., Liu, Q., Jiang, K., & Yang, G.-H. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.02.074 · Cited by 563
Worby, C. A., & Dixon, J. E. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-082411-113907 · Cited by 535
Regulation of eIF-4E BP1 Phosphorylation by mTOR
Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 527
TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function
Schalm, S. S., Fingar, D. C., Sabatini, D. M., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00329-4 · Cited by 520
Yang, Q., Inoki, K., Ikenoue, T., & Guan, K.-L. (2006) · Genes & Development · doi:10.1101/gad.1461206 · Cited by 517
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 505
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding
Wang, L., Harris, T. E., Roth, R. A., & Lawrence, J. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702376200 · Cited by 494
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 471
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 464
Hannan, K. M., Brandenburger, Y., Jenkins, A., Sharkey, K., Cavanaugh, A., Rothblum, L., Moss, T., Poortinga, G., McArthur, G. A., Pearson, R. B., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8862-8877.2003 · Cited by 460
Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 450
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain
Furnari, F. B., Lin, H., Huang, H.-J. S., & Cavenee, W. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12479 · Cited by 434
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
SH2 domains, interaction modules and cellular wiring
Pawson, T., Gish, G. D., & Nash, P. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02154-7 · Cited by 408
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria, J., Lee, H., Lee, J. I., Luo, W., Issa, J. J., Kemp, B. L., Liu, D. D., Kurie, J. M., Mao, L., & Khuri, F. R. (2002) · PubMed · Cited by 406
REGULATION OF EUKARYOTIC PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C AND PHOSPHOLIPASE D
Singer, W. D., Brown, H. A., & Sternweis, P. C. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.475 · Cited by 401
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Bunney, T. D., & Katan, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2842 · Cited by 400
Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Yaguchi, S.-I., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., & Yamori, T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj133 · Cited by 387
RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
Calne, R. Y., Lim, S., Samaan, A., Collier, D. S. J., Pollard, S. G., White, D. J. G., & Thiru, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90417-0 · Cited by 367
Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005) · Modern Pathology · doi:10.1038/modpathol.3800438 · Cited by 355
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Mutations of the human PTEN gene
Bonneau, D., & Longy, M. (2000) · Human Mutation · doi:10.1002/1098-1004(200008)16:2<109::aid-humu3>3.0.co;2-0 · Cited by 333
Common corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wu, W.-I., Voegtli, W. C., Sturgis, H. L., Dizon, F. P., Vigers, G. P. A., & Brandhuber, B. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012913 · Cited by 331
Castellanos, E., Feld, E., & Horn, L. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 313
Haddadi, N., Lin, Y., Travis, G., Simpson, A. M., Nassif, N. T., & McGowan, E. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0803-3 · Cited by 312
Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
Vadas, O., Burke, J. E., Zhang, X., Berndt, A., & Williams, R. L. (2011) · Science Signaling · doi:10.1126/scisignal.2002165 · Cited by 299
Weng, L., Smith, W. M., Dahia, P. L. M., Ziebold, U., Gil, E., Lees, J. A., & Eng, C. (1999) · PubMed · Cited by 285
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264
Maira, S.-M., Galetic, I., Brazil, D. P., Kaech, S., Ingley, E., Thelen, M., & Hemmings, B. A. (2001) · Science · doi:10.1126/science.1062030 · Cited by 263
Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 259
Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.05.006 · Cited by 243
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Janku, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 243
Tamguney, T., & Stokoe, D. (2007) · Journal of Cell Science · doi:10.1242/jcs.015230 · Cited by 234
Maximising the potential of AKT inhibitors as anti-cancer treatments
Brown, J. S., & Banerji, U. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.001 · Cited by 221
McKay, J. A., Murray, L. J., Curran, S., Ross, V. G., Clark, C., Murray, G. I., Cassidy, J., & McLeod, H. L. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00234-4 · Cited by 220
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214
Regulation of mTORC2 Signaling
Fu, W., & Hall, M. N. (2020) · Genes · doi:10.3390/genes11091045 · Cited by 213
AKT1E17K in human solid tumours
Bleeker, F. E., Felicioni, L., Buttitta, F., Lamba, S., Cardone, L., Rodolfo, M., Scarpa, A., Leenstra, S., Frattini, M., Barbareschi, M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.170 · Cited by 209
New antitumor substances of natural origin
Douros, J., & Suffness, M. (1981) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(81)80006-0 · Cited by 202
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Li, H., Zeng, J., & Shen, K. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3377-3 · Cited by 201
Regulation of mTOR by Phosphatidic Acid?
Foster, D. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3016 · Cited by 190
mTORC1 Directly Phosphorylates and Regulates Human MAF1
Michels, A. A., Robitaille, A. M., Buczynski-Ruchonnet, D., Hodroj, W., Reina, J. H., Hall, M. N., & Hernandez, N. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00319-10 · Cited by 182
Shor, B., Wu, J., Shakey, Q., Toral-Barza, L., Shi, C., Follettie, M., & Yu, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.071639 · Cited by 182
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Fan, Q., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.014 · Cited by 180
Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
Pearce, L. R., Sommer, E. M., Sakamoto, K., Wullschleger, S., & Alessi, D. R. (2011) · Biochemical Journal · doi:10.1042/bj20102103 · Cited by 179
PLD1 Regulates mTOR Signaling and Mediates Cdc42 Activation of S6K1
Fang, Y., Park, I.-H., Wu, A.-L., Du, G., Huang, P., Frohman, M. A., Walker, S. J., Brown, H. A., & Chen, J. (2003) · Current Biology · doi:10.1016/j.cub.2003.11.021 · Cited by 177
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
Zhao, W., Qiu, Y., & Kong, D. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.006 · Cited by 166
Yin, Y., Hua, H. M., Li, M., Liu, S., Kong, Q., Shao, T., Wang, J., Luo, Y., Wang, Q., Luo, T. L., et al. (2015) · Cell Research · doi:10.1038/cr.2015.133 · Cited by 152
Harnessing Allostery: A Novel Approach to Drug Discovery
Lu, S., Li, S., & Zhang, J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21317 · Cited by 148
Cryo-EM structure of human mTOR complex 2
Chen, X., Liu, M., Tian, Y., Li, J., Qi, Y., Zhao, D., Wu, Z., Huang, M., Wong, C. C. L., Wang, H., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0029-3 · Cited by 146
Grabinski, N., Ewald, F., Hofmann, B. T., Staufer, K., Schumacher, U., Nashan, B., & Jücker, M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-85 · Cited by 129
Self-citationThe Enigma of Rapamycin Dosage
Mukhopadhyay, S., Frías, M. A., Chatterjee, A., Yellen, P., & Foster, D. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0720 · Cited by 126
Bond, P. (2016) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-016-0118-y · Cited by 121
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Tourneau, C. L., Faivre, S. J., Serova, M., & Raymond, É. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604636 · Cited by 115
Nutrient sensing in the mTOR/S6K1 signalling pathway
Gulati, P., & Thomas, G. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350236 · Cited by 115
du Rusquec, P., Blonz, C., Frenel, J., & Campone, M. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920940939 · Cited by 112
Phosphatidohydrolase activity in a solubilized preparation from rat brain particulate fraction
Saito, M., & Kanfer, J. N. (1975) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(75)90346-x · Cited by 110
Hao, Y., Wang, C., Cao, B., Hirsch, B. M., Song, J. K., Markowitz, S. D., Ewing, R. M., Sedwick, D., Liu, L., Zheng, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.021 · Cited by 110
Landgraf, K. E., Pilling, C., & Falke, J. J. (2008) · Biochemistry · doi:10.1021/bi801683k · Cited by 109
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
Zhang, Y., Yan, H., Xu, Z., Yang, B., Luo, P., & He, Q. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1663169 · Cited by 105
The 3.2-Å resolution structure of human mTORC2
Scaiola, A., Mangia, F., Imseng, S., Boehringer, D., Berneiser, K., Shimobayashi, M., Stuttfeld, E., Hall, M. N., Ban, N., & Maier, T. (2020) · Science Advances · doi:10.1126/sciadv.abc1251 · Cited by 105
Architecture of the human mTORC2 core complex
Stuttfeld, E., Aylett, C. H. S., Imseng, S., Boehringer, D., Scaiola, A., Sauer, E., Hall, M. N., Maier, T., & Ban, N. (2018) · eLife · doi:10.7554/elife.33101 · Cited by 92
Huw, L.-Y., O'Brien, C. L., Pandita, A., Mohan, S., Spoerke, J. M., Lu, S., Wang, Y., Hampton, G. M., Wilson, T. R., & Lackner, M. R. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.46 · Cited by 91
Ewald, F., Grabinski, N., Grottke, A., Windhorst, S., Nörz, D. S., Carstensen, L., Staufer, K., Hofmann, B. T., Diehl, F., David, K. A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28214 · Cited by 86
Self-citationWoscholski, R., Finan, P. M., Radley, E., Totty, N. F., Sterling, A., Hsuan, J. J., Waterfield, M. D., & Parker, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.9625 · Cited by 86
Hall, C. P., Reynolds, C. P., & Kang, M. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0114 · Cited by 85
Pang, H., Flinn, R. J., Patsialou, A., Wyckoff, J. B., Torres, E. T. R., Wu, H., Pozzuto, M., Goswami, S. K., Condeelis, J. S., Bresnick, A. R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1968 · Cited by 85
Reciprocal Regulation of AMP-activated Protein Kinase and Phospholipase D
Mukhopadhyay, S., Saqcena, M., Chatterjee, A., Garcia, A., Frías, M. A., & Foster, D. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.622571 · Cited by 74
Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid
Kam, Y., & Exton, J. H. (2004) · The FASEB Journal · doi:10.1096/fj.03-0731com · Cited by 72
Oricchio, E., Katanayeva, N., Collier, M. D., Sungalee, S., Pasion, J. P., Béguelin, W., Battistello, E., Sanghvi, V. R., Jiang, M., Jiang, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9969 · Cited by 71
Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
Chen, Y., Huang, L., Dong, Y., Tao, C., Zhang, R., Shao, H., & Shen, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573599 · Cited by 65
Mechanisms of resistance to mTOR inhibitors
Formisano, L., Napolitano, F., Rosa, R., D’Amato, V., Servetto, A., Marciano, R., Placido, P. D., Bianco, C., & Bianco, R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102886 · Cited by 63
The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis
Cai, J., Xu, L., Tang, H., Yang, Q., Yi, X., Fang, Y., Zhu, Y., & Wang, Z. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0333 · Cited by 62
Mukhopadhyay, S., Chatterjee, A., Kogan, D., Patel, D., & Foster, D. A. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1087623 · Cited by 60
Kuroshima, K., Yoshino, H., Okamura, S., Tsuruda, M., Osako, Y., Sakaguchi, T., Sugita, S., Tatarano, S., Nakagawa, M., & Enokida, H. (2020) · Cancer Science · doi:10.1111/cas.14395 · Cited by 58
The mTOR (Mammalian Target of Rapamycin) Kinase Maintains Integrity of mTOR Complex 2
Chen, C.-H., & Sarbassov, D. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.282590 · Cited by 49
Gazi, M., Moharram, S. A., Marhäll, A., & Kazi, J. U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.035 · Cited by 47
Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Mallya, S., Fitch, B. A., Lee, J. S., So, L., Janes, M. R., & Fruman, D. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088865 · Cited by 42
Recent progress towards clinically relevant ATP-competitive Akt inhibitors
Huck, B. R., & Mochalkin, I. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.090 · Cited by 40
Wu, N., Du, Z., Zhu, Y., Song, Y., Pang, L., & Chen, Z. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818758772 · Cited by 40
Ca2+‐ and phospholipase D‐dependent and ‐independent pathways activate mTOR signaling
Ballou, L. M., Jiang, Y.-P., Du, G., Frohman, M. A., & Lin, R. Z. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00816-0 · Cited by 37
Manna, F. L., Menna, M. D., Patel, N., Karkampouna, S., Filippo, M. R. D., Klima, I., Kloen, P., Beimers, L., Thalmann, G. N., Pelger, R. C. M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01012 · Cited by 36
IMMUNOSUPPRESSIVE PROPERTIES OF FK-506 AND RAPAMYCIN
Thomson, A. W., & Woo, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90616-8 · Cited by 33
Bi, C., Zhang, X., Lu, T., Zhang, X., Wang, X., Meng, B., Zhang, H., Wang, P., Vose, J. M., Chan, W. C., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159160 · Cited by 32
Vargas‐Toscano, A., Nickel, A., Li, G., Kamp, M. A., Muhammad, S., Leprivier, G., Fritsche, E., Barker, R. A., Sabel, M., Steiger, H., et al. (2020) · Cancers · doi:10.3390/cancers12123859 · Cited by 31
Kim, D., Park, G., Huuhtanen, J., Lundgren, S., Khajuria, R. K., Hurtado, A. M., Muñoz‐Calleja, C., Cardeñoso, L., de Soria, V. G.-G., Chen‐Liang, T. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16115-w · Cited by 28
Li, S., Wang, Z., Huang, J. V., Cheng, S., Du, H., Che, G., & Peng, Y. (2016) · BMC Cancer · doi:10.1186/s12885-016-2940-7 · Cited by 26
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
Mancini, M., Lien, E. C., & Toker, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8191 · Cited by 25
Cao, F., Zhang, C., Han, W., Gao, X., Ma, J., Hu, Y., Gu, X., Ding, H.-Z., Zhu, L., & Liu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17001 · Cited by 19
Cited by
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian, L.-Y., Smit, D. J., & Jücker, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032652 · Cited by 329
Self-citationCurrent State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Metadata
- Authors
- Popova, N. V., & Jücker, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-09
- Volume
- 22
- Issue
- 4
- Pages
- 1743
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3128211388
- Cited by
- 267
- References
- 182
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.